European Archives - Page 191 of 1301 - European Medical Journal

Managing Atopic Dermatitis in Infants

Restoring the skin barrier is key in managing and potentially preventing atopic dermatitis.

The word spotlight on a blue background

Spotlight: April 2025

From new scientific data-sharing initiatives to US drug tariffs, May brought a range of major news to the pharma landscape.

Breast Cancer Study Tests Surgery-Free Approach

A US trial has shown no local tumour recurrences in patients with exceptional responses to neoadjuvant therapy who skipped breast surgery, offering hope for future de-escalation strategies.

New Treatment Strategy May Boost Survival in T-Cell Lymphomas

A retrospective analysis of global data has found that a specific treatment sequence, starting with small molecule inhibitors and followed by epigenetic modifiers, may significantly improve survival in patients with relapsed or refractory T-cell lymphomas.

Mirikizumab Shows Promise in Treating Inflammatory Bowel Disease

Read about how mirikizumab shows strong results for IBD, improving remission and response rates.

Expert Tone on Post-Stroke Spasticity

Tune into this episode discussing the management of post-stroke spasticity to improve patient outcomes by recognising, diagnosing, and…

Lilly partners with Alchemab for ALS candidate

Eli Lilly joins forces with Alchemab in a deal worth $415m, expanding its neuroscience pipeline with a novel candidate.

Triple-Modality Approach Offers Hope for Prostate Cancer

Early results support the theory that combining systemic and localised treatment in oligometastatic prostate cancer can improve tumour control.

Breakthrough for Bronchiectasis: Phase 2 Results of DPP-1 Inhibitor

Discover how HSK31858 could transform bronchiectasis treatment by reducing flare-ups – read more about the latest trial results.

Ultrasound-Guided Tracheostomy Cuts Complications and Boosts First-Puncture Success

Understand how ultrasound-guided PDT improves first-puncture success and reduces bleeding risk compared to landmark guidance.